Multi-Country Herpes Immunotherapy Clinical Study Continues
WEBMar 5, 2024 · This multi-country research study is recruiting 332 healthy participants aged 18-40 years or those aged 18-60 years with recurrent genital herpes. Known as GSK3943104A, GSK Study #215336 is forecasted to conclude in May 2026. This HSVTI study will explore different formulations and be conducted in two parts:
Herpes Vaccine Candidate Advances in 2023 - Precision …
WEBJan 8, 2023 · When BioNTech SE announced that the first person was dosed in a first-in-human Phase 1 clinical trial with BNT163, a herpes simplex virus (HSV) vaccine candidate for the prevention of genital lesions caused by HSV-2 and potentially HSV-1, there was much enthusiasm generated by millions of people. BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on ...
34 Countries Identified in the Latest Polio Outbreak Alert
WEBJun 22, 2024 · The Global Polio Eradication Initiative (GPEI) released its weekly update, which indicated that three countries reported new polio cases as the poliovirus continues to spread in 2024. On June 19, 2024, the GPEI reported that Afghanistan confirmed one wild poliovirus type 1 (WPV1), bringing the total number of cases in 2024 to six. Nigeria reported three cases of circulating vaccine-derived ...
HSV Treatment Readies for Approval — Precision Vaccinations News
WEBMar 29, 2023 · A recently published Original Article reported positive news regarding the First-in-Human clinical trials assessing Pritelivir, a Nonnucleoside Helicase-Primase Inhibitor targeting the Herpes Simplex Virus (HSV). As an active ingredient in a new chemical class (thiazolylamides), Pritelivir is active against both types of …
Three Novel Immune-based Therapies for HIV Cure Launch Clinical …
WEBApr 22, 2024 · To address this clinical need, ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of A5374, a phase 1/2a study evaluating the safety, tolerability, and antiviral effect of a novel combination regimen that includes therapeutic T-cell vaccines, two broadly neutralizing antibodies ...
Second Generation Smallpox Vaccine Now Approved for Mpox …
WEBAug 30, 2024 · (Precision Vaccinations News) Emergent BioSolutions Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application for the expansion of the indication for the single-dose ACAM2000® Smallpox vaccine to include the prevention of mpox disease in individuals determined to be at high risk for mpox infection.
U.S. Government Takes Herpes Vaccine Development Lead
WEBApr 4, 2024 · To address this shortcoming, the U.S. government issued a Notice of Special Interest (NOSI) NOT-AI-24-028 on March 27, 2024, intending to stimulate additional focus on developing diagnostics, therapeutics, and vaccines targeting HSV. This NOSI, issued by the U.S. National Institute of Allergy and Infectious Diseases, focuses on furthering the ...
Vaccine Certificates Can Curtail Yellow Fever Outbreaks
WEB4 days ago · In 2023, over 60 million individuals received vaccinations under the WHO's Eliminate Yellow Fever Epidemics strategy. The U.S. CDC says Sanofi Pasteur's YF-VAX® vaccine is safe and highly effective and is recommended for most travelers aged nine months and older. Vaccination provides effective immunity within 30 days for 99% of …
What’s the Difference Between Shingles and Chickenpox Vaccines?
WEBNov 2, 2017 · Conversely, the Zostavax, the traditional chickenpox vaccine, offers protection against shingles by only 51 percent, and the risk of PHN by 67 percent, according to the CDC. In addition, Zostavax’s effectiveness appears to last just five years, according to the CDC. Like every vaccine, Shingrix has the potential for side effects.
mRNA-Based Flu Shot Focuses on Improving Performance in …
WEBApril 4, 2024 • 9:47 am CDT. As influenza vaccine producers prepare for the 2024 - 2025 flu season, innovative vaccine candidates are progressing in clinical research, focused on enhancing efficacy and safety. CureVac N.V. today announced interim data from an ongoing Phase 2 study, which is part of the combined Phase 1/2 study of its seasonal ...
- Some results have been removed